Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1. - Wikidata - wikimedia - TriplyDB

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

http://www.wikidata.org/entity/Q39282659

about

Trial watch - inhibiting PARP enzymes for anticancer therapy Is the Canonical RAF/MEK/ERK Signaling Pathway a Therapeutic Target in SCLC?Targeted drugs in small-cell lung cancer Small cell lung cancer (SCLC): no treatment advances in recent years Cellular and molecular biology of small cell lung cancer: an overview Novel therapies in small cell lung cancer Origins, genetic landscape, and emerging therapies of small cell lung cancer Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin Genomic profiling of small-cell lung cancer: the era of targeted therapies Activation of the PI3K/mTOR Pathway following PARP Inhibition in Small Cell Lung Cancer Histopathological transformation to small-cell lung carcinoma in non-small cell lung carcinoma tumors Pharmacogenomic approach to identify drug sensitivity in small-cell lung cancer Combinations of PARP Inhibitors with Temozolomide Drive PARP1 Trapping and Apoptosis in Ewing's Sarcoma A comprehensive comparison of normalization methods for loading control and variance stabilization of reverse-phase protein array data.A phase 1 safety study of veliparib combined with cisplatin and etoposide in extensive stage small cell lung cancer: A trial of the ECOG-ACRIN Cancer Research Group (E2511).Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers.A murine preclinical syngeneic transplantation model for breast cancer precision medicine.PARP1 expression drives the synergistic antitumor activity of trabectedin and PARP1 inhibitors in sarcoma preclinical models.Co-expression network analysis identifies Spleen Tyrosine Kinase (SYK) as a candidate oncogenic driver in a subset of small-cell lung cancer Strategies for the Use of Poly(adenosine diphosphate ribose) Polymerase (PARP) Inhibitors in Cancer Therapy.Molecular pathways and therapeutic targets in lung cancer Dynamic variations in epithelial-to-mesenchymal transition (EMT), ATM, and SLFN11 govern response to PARP inhibitors and cisplatin in small cell lung cancer.Alternative mammalian target of rapamycin (mTOR) signal activation in sorafenib-resistant hepatocellular carcinoma cells revealed by array-based pathway profiling In silico identification of potential key regulatory factors in smoking-induced lung cancer.Combination Platinum-based and DNA Damage Response-targeting Cancer Therapy: Evolution and Future Directions.Small cell lung cancer: where do we go from here?Small cell lung cancer: therapies and targets A comprehensive evaluation of biomarkers predictive of response to PI3K inhibitors and of resistance mechanisms in head and neck squamous cell carcinoma.Clinical significance of NQO1 polymorphism and expression of p53, SOD2, PARP1 in limited-stage small cell lung cancer Mechanistic relationships between hepatic genotoxicity and carcinogenicity in male B6C3F1 mice treated with polycyclic aromatic hydrocarbon mixtures.Genomic deregulation of the E2F/Rb pathway leads to activation of the oncogene EZH2 in small cell lung cancer.Poly (ADP) ribose polymerase enzyme inhibitor, veliparib, potentiates chemotherapy and radiation in vitro and in vivo in small cell lung cancer.Genomic pathway analysis reveals that EZH2 and HDAC4 represent mutually exclusive epigenetic pathways across human cancers Molecularly targeted therapies in non-small-cell lung cancer annual update 2014 RB loss in resistant EGFR mutant lung adenocarcinomas that transform to small-cell lung cancer.New paradigms in the repair of oxidative damage in human genome: mechanisms ensuring repair of mutagenic base lesions during replication and involvement of accessory proteins.Oncoproteomics: Trials and tribulations.Small cell lung cancer: will recent progress lead to improved outcomes?An Integrated Molecular Analysis of Lung Adenocarcinomas Identifies Potential Therapeutic Targets among TTF1-Negative Tumors, Including DNA Repair Proteins and Nrf2.DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.

P2860

Q38568854-CCFE1880-F302-4C4B-B9EF-61342488A9B4 Q4649475-2A71B310-9707-4812-A3AF-7244E59820CE Q52392355-91926ACC-BA3C-414F-9A54-98A624576D4A Q54808423-E3B721EA-C105-4AE5-A3E0-BC4CB7377B11 Q54808427-B4975ACB-4BF4-4C71-B0DA-9E8F88087F0F Q54831291-68A51835-41DC-4284-AAE7-CAE0E238CB24 Q54831295-9EEA2CB7-8DAE-45D9-8A12-2B4D32643F5C Q54831310-E5533FCF-714E-4BB0-953C-CA725A012E03 Q54831312-540061FD-6E2A-4922-B1A3-461941EAC5A5 Q54832197-95100983-1DC5-4AD0-BCC0-E8590C9D8B5A Q54881534-7D163572-1B6A-4199-9CDA-DAAFD2FEE030 Q54881541-405001FD-077B-461D-879F-B36E607D7A32 Q54881559-65AE6122-F7A4-4646-ABC4-ACD42AE6FCDD Q54881579-F80BD3E7-4B6C-486B-98C6-44CDAAB78910 Q54881611-5D8FAC7D-53F1-4AA4-84DC-E935A4984FCA Q54881640-5667B21B-1D36-494A-9D30-4D376D9F050C Q54881680-21AE836F-67CD-4F0B-8223-286783DFBC53 Q54881692-96059D78-5088-4ED1-AC03-1C55BC28CA3B Q54881708-196FE4B1-29CF-4F70-8B16-76BFAA7CDA5C Q54881724-8947D1AE-0199-446F-B52E-F2B96CC55173 Q54881731-54C482CC-CA0E-484E-983B-F1A7549C2D72 Q54881736-1618F54B-1A84-4054-B85D-6A9F355C1DD4 Q54881754-2267D778-25AA-40F0-A1F7-BD6A23B8567F Q54881757-ABAA08C4-8809-422B-98A8-373BA4F8E325 Q54881759-B574E1E5-EB88-46AB-B394-862CF5EF950F Q54881777-D81CBEA3-2779-4262-807A-A4DE2458BCD7 Q54881781-A4116220-52BF-4630-862B-7074455F5359 Q54881826-D4659BCE-ADAC-4417-B9BD-658EEBD04C1C Q54890155-6A6CE3CE-66EF-4A09-A1A3-32B71071584A Q54890156-5C06C21B-BF56-4F7F-9049-E107018D199E Q54907769-4914EFA8-476B-4768-910F-8098F3BAB950 Q54907773-4E8DD480-A464-4C62-BBBD-80625D64CC5B Q54907779-A6D132E8-91D7-4492-8471-2C39B5D7A7CE Q54907786-57EA3104-28E0-422C-BDAC-FF57444AC940 Q54907795-37862FBC-599F-4013-9FA4-ED149ADC407B Q54907796-2E77C76D-C04D-4A70-A52B-45A08FBDAC56 Q54907805-53F72D33-8EBE-48A5-931A-FFB36D143912 Q54907808-C4A9E51B-C9E9-4E8B-A363-080F39DB9F09 Q54907813-32A82CF4-40F2-49AE-AB7B-EAA125820EE1 Q54907820-4297F30D-24A5-489A-A24C-36DE79D5DCDC

P1343

Q26745673-BA1531AF-5127-4DDF-B13D-A6C9DAFC34A6 Q26748741-A24E3CDD-DB1E-4F8F-8634-6D3C81A110D4 Q26767017-369804FF-E89B-4EE4-89BC-1296477F952C Q26767020-46FD51B7-2730-4532-9C74-F521560B4519 Q26767029-08ADA883-0BC4-43A5-8B42-8941ED48283B Q26775390-15D6A7DB-A47B-49AB-9A11-298A80210293 Q26798218-F57128B1-2AAA-479C-91FF-EB2EA8CFF680 Q26826437-A7E7ED0E-8A06-41B8-B7C0-3B15D91BFA9D Q26826915-80781E1C-7BF9-4316-A979-40DBF21586BC Q27315948-A4216EE2-15BC-4499-A0C4-281C65428AA4 Q28077504-7D827836-A3EC-4766-9D3A-739D36095095 Q28542859-F6EFDDEA-9E80-49AC-A26D-F78C0D0C1093 Q28550512-7F003495-3260-4C3D-933D-16654962402F Q30867943-14A5D4D0-DFE5-41D3-91BB-F07CBE51BB78 Q33422932-3EFE0BE8-8325-4EFE-B76F-6CE9905C84E1 Q33439705-85140EC5-31CC-4932-853A-150EB6F8E076 Q33580224-3E22ED61-BCEF-4FD9-81E5-249E37548EB1 Q33617922-26E85A0F-EBF5-4665-B2EF-CB1B49D079EB Q33643375-05B61319-5049-490B-BBF9-55C07814C593 Q33649555-D0C00772-11EC-4199-8EC1-C13955168CAA Q33688872-2B95CA8B-C373-4CD9-A3F4-ED746D8DB535 Q33709790-0EE5EA30-5EEC-42B5-BBE1-E8A036EDB3AF Q33718695-3823B450-DD27-4E86-A09B-852BBB475CCA Q33776567-3A2FC582-4152-4916-A34E-F05AC788592D Q33798999-F0C4530E-B9E3-4990-83F8-735FCD8E82DD Q33872327-B7BCF05F-DC6E-4519-96BC-F90765FB3EE5 Q34250859-1FFCCB3A-75DE-4B8A-9720-03AA849F194C Q34458117-5AABE5E2-C98A-4F7F-AD89-8366B891F60D Q34502009-3955A246-3D23-4BA5-A3C9-18FB5D4E956B Q34627161-2DEC3B4A-FE13-43F4-905C-7AC01764E913 Q34964303-EBD060BE-9862-4D0B-A1CA-90670A97CF21 Q34982593-6E8B7F50-765F-4A31-946C-C274204BAF5D Q35002412-B1C025F5-8C36-4EFC-A6F5-EAE4F883F95D Q35136424-15989F7B-D017-4E02-A7D4-19864E7C4A05 Q35170413-BD135DDF-9C0F-4287-914E-971E1EB65A73 Q35395549-C2085AEE-D743-4BE8-A5B2-940BE735AEFE Q35827653-0FCFF69C-190E-45BE-9967-4DA181C6B8E2 Q35836257-21CA8557-5688-4282-B338-A03157E06FAC Q35920986-EE7A190C-9658-418D-9F6D-99FEFF24C3E5 Q36042596-077295B4-8867-41B5-BFE8-C9173698D754

P2860

Proteomic profiling identifies dysregulated pathways in small cell lung cancer and novel therapeutic targets including PARP1.

http://www.wikidata.org/entity/Q39282659

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

2012年论文

@zh

2012年论文

@zh-cn

name

Proteomic profiling identifies ...... eutic targets including PARP1.

@en

Proteomic profiling identifies ...... eutic targets including PARP1.

@nl

type

label

Proteomic profiling identifies ...... eutic targets including PARP1.

@en

Proteomic profiling identifies ...... eutic targets including PARP1.

@nl

prefLabel

Proteomic profiling identifies ...... eutic targets including PARP1.

@en

Proteomic profiling identifies ...... eutic targets including PARP1.

@nl

P1433

Q39282659-8C8D82E3-E172-48AE-8B88-679F64AC84E5

P1476

Q39282659-2DB51D87-5DC8-47EC-B3A5-3DD0575C92C0

P2093

Q39282659-031E469B-32C2-47AF-931E-3026F231B5C5

Q39282659-039F7F90-0577-47AC-A39D-F23B4D865096

Q39282659-2FEAD24E-5699-45C3-9546-C8638395C684

Q39282659-34CFC110-5AE5-47AF-8C29-CC8EC0D49B94

Q39282659-3862DBE3-40F8-41DC-9CED-AE9E5214BA24

Q39282659-3BBBC20D-8B52-49D4-AA31-10C986D72D89

Q39282659-590278E2-0181-4427-8381-3A873B43C975

Q39282659-5AA56EF3-9377-4F03-9C37-916F0BA7B6E7

Q39282659-5F1FF603-DFE4-4C19-A129-1EA7B7AC67D8

Q39282659-68058255-A727-4068-87C6-1EDEBB045701

P2860

Q39282659-10271DB7-8E75-4A95-B712-4CECDD36990A

Q39282659-1DE7F055-F110-4171-B405-B662B40393CF

Q39282659-21DCBF18-6AFB-4FC6-A525-6294CE9E8719

Q39282659-26877E4A-A70F-4A57-A2D0-C16EE0F5BB85

Q39282659-2868760C-5840-4B88-88C6-3DEB2D9761F3

Q39282659-3050ECBC-DACC-48ED-BA91-2A6059063A14

Q39282659-31AFF9C1-91BB-43BE-9EC0-9FDD79FE155D

Q39282659-341277A1-EE3D-4993-9488-7FAC94BC5C93

Q39282659-4044C16A-6B83-48F2-94B6-BDB4ADFD1AB4

Q39282659-43C74C1C-BA83-4D66-9EFB-E18CE846C74D

P304

Q39282659-0FA08C1D-76AC-4AFA-A1FB-700E5491F1A7

P31

Q39282659-E783399D-F8DE-4E29-BD43-E817162649E6

P356

Q39282659-A119B0F1-FA99-477D-AD51-201F673F7109

P433

Q39282659-E7770B75-54D5-4B06-A780-E57B5DEF82F3

P4510

Q39282659-01105E50-A494-4FE5-9D97-B354720B69F5

Q39282659-02C6281B-92FC-46F6-A51B-F114FE12FBDB

Q39282659-054AD2A6-E3DA-45A5-9B3A-44CC0A42E9CF

Q39282659-09A40DA8-65D2-40CB-81E4-C27B85DA065D

Q39282659-0C5A782D-50B1-4718-B165-BBE5DE473349

Q39282659-10454364-2D29-4F12-8EAA-46F7D5BEC37A

Q39282659-11B84AFF-40A2-40D6-B5D9-E14BCA2CEFB1

Q39282659-11D3FE32-C53B-499B-A765-D968D345D903

Q39282659-12BB31D2-9957-4296-B792-E9DA697E6D15

Q39282659-15890920-7B25-4735-BD29-6683D085420F

P478

Q39282659-17D4181A-2FEF-41F7-AEDF-C3E5CBC85FCA

P50

Q39282659-12448BB8-8529-4722-8C1D-E43F711A69C0

Q39282659-57782DB7-F6E6-43E9-BB1B-8745BF5D2FBD

Q39282659-FA842EDC-1CDF-438A-8659-8EB3ED89BFB0

P577

Q39282659-8E74C521-A956-41FD-A9CB-838B55A7C52F

P698

Q39282659-D513D288-F826-4D94-8C99-62151ACB3CBA

P921

Q39282659-96EBA11F-9814-4A6C-B2BA-96CB3ECFBDDF

P932

Q39282659-BC781106-3A05-4464-95B0-163D875DA825

P356

2159-8290.CD-12-0112

P1433

Cancer Discovery

P1476

Proteomic profiling identifies ...... eutic targets including PARP1.

@en

P2093

Bonnie S Glisson

http://www.w3.org/2001/XMLSchema#string

Boris Duchemann

http://www.w3.org/2001/XMLSchema#string

Fatemeh Masrorpour

http://www.w3.org/2001/XMLSchema#string

Gordon B Mills

http://www.w3.org/2001/XMLSchema#string

James Welsh

http://www.w3.org/2001/XMLSchema#string

Jing Wang

http://www.w3.org/2001/XMLSchema#string

John D Minna

http://www.w3.org/2001/XMLSchema#string

John N Weinstein

http://www.w3.org/2001/XMLSchema#string

John Yordy

http://www.w3.org/2001/XMLSchema#string

Junya Fujimoto

http://www.w3.org/2001/XMLSchema#string

P2860

PARP-1 binds E2F-1 independently of its DNA binding and catalytic domains, and acts as a novel coactivator of E2F-1-mediated transcription during re-entry of quiescent cells into S phase

EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib

NCBI GEO: archive for functional genomics data sets--10 years on

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer.

Inhibition of poly(ADP-ribose) polymerase in tumors from BRCA mutation carriers.

Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Gene Expression Omnibus: NCBI gene expression and hybridization array data repository

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

Systematic identification of genomic markers of drug sensitivity in cancer cells

P304

798-811

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1158/2159-8290.CD-12-0112

http://www.w3.org/2001/XMLSchema#string

P433

9

http://www.w3.org/2001/XMLSchema#string

P4510

P478

2

http://www.w3.org/2001/XMLSchema#string

P50

Kevin R. Coombes

Ignacio I Wistuba

P577

2012-09-06T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

22961666

http://www.w3.org/2001/XMLSchema#string

P921

P932

3567922

http://www.w3.org/2001/XMLSchema#string